Search Results - "Soeda, Tetsuhiro"

Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens by Kitazawa, Takehisa, Esaki, Keiko, Tachibana, Tatsuhiko, Ishii, Shinya, Soeda, Tetsuhiro, Muto, Atsushi, Kawabe, Yoshiki, Igawa, Tomoyuki, Tsunoda, Hiroyuki, Nogami, Keiji, Shima, Midori, Hattori, Kunihiro

“…Emicizumab, a humanised bispecific antibody recognising factors (F) IX/IXa and X/Xa, can accelerate FIXa-catalysed FX activation by bridging FIXa and FX in a…”
Get more information

Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity by Sampei, Zenjiro, Igawa, Tomoyuki, Soeda, Tetsuhiro, Okuyama-Nishida, Yukiko, Moriyama, Chifumi, Wakabayashi, Tetsuya, Tanaka, Eriko, Muto, Atsushi, Kojima, Tetsuo, Kitazawa, Takehisa, Yoshihashi, Kazutaka, Harada, Aya, Funaki, Miho, Haraya, Kenta, Tachibana, Tatsuhiko, Suzuki, Sachiyo, Esaki, Keiko, Nabuchi, Yoshiaki, Hattori, Kunihiro

“…In hemophilia A, routine prophylaxis with exogenous factor VIII (FVIII) requires frequent intravenous injections and can lead to the development of anti-FVIII…”
Get full text

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model by Kitazawa, Takehisa, Igawa, Tomoyuki, Sampei, Zenjiro, Muto, Atsushi, Kojima, Tetsuo, Soeda, Tetsuhiro, Yoshihashi, Kazutaka, Okuyama-Nishida, Yukiko, Saito, Hiroyuki, Tsunoda, Hiroyuki, Suzuki, Tsukasa, Adachi, Hideki, Miyazaki, Taro, Ishii, Shinya, Kamata-Sakurai, Mika, Iida, Takeo, Harada, Aya, Esaki, Keiko, Funaki, Miho, Moriyama, Chifumi, Tanaka, Eriko, Kikuchi, Yasufumi, Wakabayashi, Tetsuya, Wada, Manabu, Goto, Masaaki, Toyoda, Takeshi, Ueyama, Atsunori, Suzuki, Sachiyo, Haraya, Kenta, Tachibana, Tatsuhiko, Kawabe, Yoshiki, Shima, Midori, Yoshioka, Akira, Hattori, Kunihiro

“…Individuals with hemophilia A lack the coagulation factor FVIII and are treated with frequent intravenous injections of FVIII agents. However, many individuals…”
Get full text

A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X by Ogiwara, Kenichi, Nogami, Keiji, Matsumoto, Naoki, Noguchi-Sasaki, Mariko, Hirata, Michinori, Soeda, Tetsuhiro, Shima, Midori

“…Emicizumab shortens activated partial thromboplastin time (aPTT) greater than Factor (F)VIII. Clot waveform analysis triggered by ellagic acid and tissue…”
Get full text

Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A by Muto, Atsushi, Yoshihashi, Kazutaka, Takeda, Minako, Kitazawa, Takehisa, Soeda, Tetsuhiro, Igawa, Tomoyuki, Sampei, Zenjiro, Kuramochi, Taichi, Sakamoto, Akihisa, Haraya, Kenta, Adachi, Kenji, Kawabe, Yoshiki, Nogami, Keiji, Shima, Midori, Hattori, Kunihiro

“…ACE910 is a humanized anti-factor IXa/X bispecific antibody mimicking the function of factor VIII (FVIII). We previously demonstrated in nonhuman primates that…”
Get full text

A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state by Teranishi-Ikawa, Yuri, Soeda, Tetsuhiro, Koga, Hikaru, Yamaguchi, Kazuki, Kato, Kazuki, Esaki, Keiko, Asanuma, Kentaro, Funaki, Miho, Ichiki, Mina, Ikuta, Yuri, Ito, Shunsuke, Joyashiki, Eri, Komatsu, Shun-Ichiro, Muto, Atsushi, Nishimura, Kei, Okuda, Momoko, Sanada, Hisakazu, Sato, Motohiko, Shibahara, Norihito, Wakabayashi, Tetsuya, Yamaguchi, Koji, Matsusaki, Akiko, Sampei, Zenjiro, Shiraiwa, Hirotake, Konishi, Hiroko, Kawabe, Yoshiki, Hattori, Kunihiro, Kitazawa, Takehisa, Igawa, Tomoyuki

“…Emicizumab, a factor (F) VIIIa-function mimetic bispecific antibody (BsAb) to FIXa and FX, has become an indispensable treatment option for people with…”
Get full text

Emicizumab improves the stability and structure of fibrin clot derived from factor VIII‐deficient plasma, similar to the addition of factor VIII by Shimonishi, Naruto, Nogami, Keiji, Ogiwara, Kenichi, Matsumoto, Tomoko, Nakazawa, Fumie, Soeda, Tetsuhiro, Hirata, Michinori, Arai, Nobuo, Shima, Midori

“…Introduction Emicizumab is an antifactor (F)IXa/FX bispecific antibody, mimicking FVIIIa cofactor function. Emi prophylaxis effectively reduces bleeding events…”
Get full text

The factor VIII heavy chain improves emicizumab-tenase assembly to enhance the factor VIII-mimicking cofactor activity by Minami, Hiroaki, Nogami, Keiji, Soeda, Tetsuhiro, Kitazawa, Takehisa, Hattori, Kunihiro, Shima, Midori

Get full text

The use of infrared thermography for non-invasive detection of bleeding and musculoskeletal abnormalities in patients with hemophilia: an observational study by Kawasaki, Ryohei, Sakata, Asuka, Hosoda, Chihiro, Harada, Suguru, Soeda, Tetsuhiro, Nishida, Yukiko, Matsumoto, Naoki, Tatsumi, Kohei, Nogami, Keiji, Yoshimura, Yasushi, Shima, Midori

“…In patients with hemophilia (PwH), bleeding often occurs in joints and muscles, and early detection of hemorrhage is important to prevent the onset and…”
Get full text

A Novel Clot Waveform Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-Fixa/Fx Bispecific Antibody, Emicizumab by Nogami, Keiji, Matsumoto, Tomoko, Tabuchi, Yuka, Soeda, Tetsuhiro, Arai, Nobuo, Kitazawa, Takehisa, Takaoka, Hidenari, Hattori, Kunihiro, Shima, Midori

“…Emicizumab (also termed ACE910) is a humanized anti-factor (F)IXa/FX bispecific antibody with FVIIIa cofactor function. A clinical phase 3 study was initiated…”
Get full text

Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan by Matsumoto, Naoki, Abe, Hiroto, Kawasaki, Ryohei, Tashiro, Yoshihito, Noguchi-Sasaki, Mariko, Harada, Suguru, Yoneyama, Koichiro, Niino, Tomomi, Soeda, Tetsuhiro, Yoshimura, Yasushi

Get full text

The Factor VIIIa C2 Domain (Residues 2228–2240) Interacts with the Factor IXa Gla Domain in the Factor Xase Complex by Soeda, Tetsuhiro, Nogami, Keiji, Nishiya, Katsumi, Takeyama, Masahiro, Ogiwara, Kenichi, Sakata, Yoichi, Yoshioka, Akira, Shima, Midori

“…Factor VIIIa functions as a cofactor for factor IXa in the phospholipid surface-dependent activation of factor X. Both the C2 domain of factor VIIIa and the…”
Get full text

Noninvasive mapping of reactive oxygen species by in vivo electron spin resonance spectroscopy in indomethacin-induced gastric ulcers in rats by Utsumi, Hideo, Yasukawa, Keiji, Soeda, Tetsuhiro, Yamada, Ken-ichi, Shigemi, Ryota, Yao, Takashi, Tsuneyoshi, Masazumi

“…Reactive oxygen species (ROS) are thought to be involved in the gastric ulcer formation induced by indomethacin, a typical nonsteroidal anti-inflammatory drug…”
Get more information

Interactions between residues 2228-2240 within factor VIIIa C2 domain and factor IXa Gla domain contribute to propagation of clot formation by Soeda, T, Nogami, K, Ogiwara, K, Shima, M

“…Factor (F)VIII functions as a cofactor in the tenase complex responsible for phospholipid (PL)-dependent FXa generation by FIXa. We have recently reported that…”
Get more information

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro by Noguchi-Sasaki, Mariko, Soeda, Tetsuhiro, Ueyama, Atsunori, Muto, Atsushi, Hirata, Michinori, Kitamura, Hidetomo, Fujimoto-Ouchi, Kaori, Kawabe, Yoshiki, Nogami, Keiji, Shima, Midori, Kitazawa, Takehisa

“…Emicizumab is a humanized bispecific antibody that binds simultaneously to factor (F) IXa and FX replacing the cofactor function of FVIIIa. Because emicizumab…”
Get full text

Factor VIII contributes to platelet-fibrin thrombus formation via thrombin generation under low shear conditions by Sugita, Chihiro, Yamashita, Atsushi, Moriguchi-Goto, Sayaka, Furukoji, Eiji, Takahashi, Misaki, Harada, Aya, Soeda, Tetsuhiro, Kitazawa, Takehisa, Hattori, Kunihiro, Tamura, Shozo, Asada, Yujiro

“…Abstract Introduction Thrombus growth under low blood flow velocity plays an important role in the development of deep venous thrombosis (DVT). Increased…”
Get full text

A Healthy Volunteer-Derived, Factor VIII-Neutralized, Acquired Hemophilia a-Mimetic Plasma Produces Similar Pharmacodynamic Responses of Emicizumab to Those in Patients with Congenital Hemophilia a with or without Inhibitors by Yoneyama, Koichiro, Tokuda, Kazuo, Soeda, Tetsuhiro, Saito, Tomohisa, Shima, Midori

“…Emicizumab is a bispecific antibody that mimics the cofactor function of activated factor VIII (FVIIIa) and is currently indicated for routine prophylaxis of…”
Get full text

Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro by Yada, Koji, Fujitate, Natsume, Ogiwara, Kenichi, Soeda, Tetsuhiro, Kitazawa, Takehisa, Nogami, Keiji

“…The hemostatic effect of recombinant (r) factor (F)VIIa after repetitive intermittent administration may be attenuated in patients with hemophilia A (PwHA)…”
Get full text

Quantitative Estimation of the In Vivo Equivalent Factor VIII Activity of NXT007, an Emicizumab-Based, Next-Generation, Activated Factor VIII-Mimetic Bispecific Antibody, from Nonclinical Data by Yoneyama, Koichiro, Soeda, Tetsuhiro, Yamaguchi, Kazuki, Miwa, Takuya, Ishida, Takaaki, Saito, Tomohisa

Get full text

The protective effect of anti-VEGF-A/Ang-2 bispecific antibody on retinal vein occlusion model mice by Kuriyama, Aika, Nakamura, Shinsuke, Inokuchi, Yuta, Abe, Hiroto, Yasuda, Hiroto, Hidaka, Yae, Nagaoka, Koki, Soeda, Tetsuhiro, Shimazawa, Masamitsu, Hara, Hideaki

“…(233/250) Retinal vein occlusion (RVO) causes macular edema and retinal ischemia resulting in visual field and vision loss. A bispecific antibody that blocks…”
Get full text